NHEJ信号通路关键基因mRNA表达与宫颈鳞癌同步放化疗敏感性的关系

Association between mRNA expression of genes of the NHEJ pathway and response to concurrent chemoradiotherapy in squamous cell cervical carcinoma

探讨NHEJ信号通路关键基因XRCC4,XRCC5,XRCC6,LIG4,PRKDC及DCLRE1C的mRNA表达水平与宫颈鳞癌同步放化疗敏感性的关系。以42例宫颈鳞癌活检样本为研究对象,采用荧光定量PCR(qRT-PCR)技术分析上述6个基因的mRNA表达水平,并将检测结果与患者的同步放化疗敏感性进行关联分析。XRCC6 mRNA高表达患者应答率为47.6%,低表达患者应答率为90.5%(P=0.003);其他5个关键基因的mRNA表达水平与患者的应答率无显著性关联;多因素Logistic回归分析显示XRCC6 mRNA表达水平与患者同步放化疗敏感性有显著性关联(P=0.008)。XRCC6 mRNA表达水平与宫颈鳞癌患者同步放化疗敏感性密切相关,可作为评估其临床疗效的分子标志物。

To investigate the association between mRNA expression levels of genes including XRCC4,XRCC5,XRCC6,LIG4,PRKDC and DCLRE1 C involved in non-homologous end joining（ NHEJ） pathway and the sensitivity of concurrent chemoradiotherapy in squamous cell cervical carcinoma. The mRNA levels of 6 genes listed were analyzed by quantitative realtime PCR（ qRT-PCR） in pre-treatment biopsies obtained from 42 squamous cervical cancer patients,and the association between mRNA levels and the response of concurrent chemoradiotherapy were further investigated. The response rate was 47. 6% in patients with high XRCC6 mRNA expression level and 90. 5% in patients with low mRNA expression level of XRCC6（ P = 0. 003）. No statistically association was identified between the response rate and the mRNA expression level in each of the rest five genes. Multiple logistic regression analysis also reveled that the expression of XRCC6 mRNA level was significantly associated with the response to concurrent chemoradiotherapy（ P = 0. 008）. The results showed that the expression of XRCC6 mRNA was closely consistented with the sensitivity to concurrent chemoradiotherapy,suggesting that XRCC6 can be used as a predictive molecular marker in the clinical treatment of squamous cell cervical carcinoma.